Prognostic Indicators of Survival in Advanced Endometrial Cancer

Kian Behbakht, Edgardo L. Yordan, Caroline Casey, Koenraad De Geest, L. Stewart Massad, Caroline V. Kirschner, George D. Wilbanks

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Advanced endometrial cancer represents 14% of all stages but 54% of all deaths attributed to endometrial cancer. From 1973 to 1990, the charts of 137 patients with endometrial cancer (Stage III and IV) treated by the section of Gynecologic Oncology at Rush Medical College were retrospectively reviewed. The log rank method was used for univariate analysis and Cox proportional hazards regression was used for multivariate analysis. The patients were stratified as follows: Stage III, 92 (67.2%), Stage IV, 45 (32.8%); Grade 1, 15 (10.9%), Grade 2, 47 (34.3%), Grade 3, 67 (48.9%); adenocarcinoma, 93 (67.9%), adenosquamous, 18 (13.1%), adenoacanthoma, 2 (1.5%), clear cell, 1 (0.7%), papillary serous, 23 (16.8%). Using univariate analysis, median survival was 1.71 years for Stage III versus 0.68 years for Stage IV. Median survival based on treatment was as follows: radiotherapy (RT) only (n = 16), 0.89 years, surgery only (n = 36), 0.75 years, preoperative RT + surgery (n = 7), 2.5 years, surgery + postoperative RT (n = 56), 2.63 years, and other treatments (hormonal only n = 12, chemotherapy only n = 1, and no treatment n = 9), 0.6 years. Patients with vaginal extension survived a median of 0.82 years, versus 2.49 years without this factor (P = 0.002). Patients with clinically apparent parametrial involvement survived a median of 0.70 years versus 2.65 years without this factor (P = 0.0003). Multivariate analysis was possible via a surgical database (n = 99). Age >60 (P = 0.01), parametrial involvement (P = 0.04), and abdominal metastases (P = 0.003) were significant prognostic indicators. Papillary or clear cell histology, advanced grade, and mode of treatment were not significant. Patients with abdominal metastases or parametrial extension of tumor have a significant decrease in mean survival.

Original languageEnglish (US)
Pages (from-to)363-367
Number of pages5
JournalGynecologic Oncology
Volume55
Issue number3
DOIs
StatePublished - Dec 1994
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Survival
Radiotherapy
Multivariate Analysis
Neoplasm Metastasis
Therapeutics
Survival Analysis
Histology
Adenocarcinoma
Databases
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Behbakht, K., Yordan, E. L., Casey, C., De Geest, K., Massad, L. S., Kirschner, C. V., & Wilbanks, G. D. (1994). Prognostic Indicators of Survival in Advanced Endometrial Cancer. Gynecologic Oncology, 55(3), 363-367. https://doi.org/10.1006/gyno.1994.1307

Prognostic Indicators of Survival in Advanced Endometrial Cancer. / Behbakht, Kian; Yordan, Edgardo L.; Casey, Caroline; De Geest, Koenraad; Massad, L. Stewart; Kirschner, Caroline V.; Wilbanks, George D.

In: Gynecologic Oncology, Vol. 55, No. 3, 12.1994, p. 363-367.

Research output: Contribution to journalArticle

Behbakht, K, Yordan, EL, Casey, C, De Geest, K, Massad, LS, Kirschner, CV & Wilbanks, GD 1994, 'Prognostic Indicators of Survival in Advanced Endometrial Cancer', Gynecologic Oncology, vol. 55, no. 3, pp. 363-367. https://doi.org/10.1006/gyno.1994.1307
Behbakht K, Yordan EL, Casey C, De Geest K, Massad LS, Kirschner CV et al. Prognostic Indicators of Survival in Advanced Endometrial Cancer. Gynecologic Oncology. 1994 Dec;55(3):363-367. https://doi.org/10.1006/gyno.1994.1307
Behbakht, Kian ; Yordan, Edgardo L. ; Casey, Caroline ; De Geest, Koenraad ; Massad, L. Stewart ; Kirschner, Caroline V. ; Wilbanks, George D. / Prognostic Indicators of Survival in Advanced Endometrial Cancer. In: Gynecologic Oncology. 1994 ; Vol. 55, No. 3. pp. 363-367.
@article{1315886f69864cfcabec2db17a0e2482,
title = "Prognostic Indicators of Survival in Advanced Endometrial Cancer",
abstract = "Advanced endometrial cancer represents 14{\%} of all stages but 54{\%} of all deaths attributed to endometrial cancer. From 1973 to 1990, the charts of 137 patients with endometrial cancer (Stage III and IV) treated by the section of Gynecologic Oncology at Rush Medical College were retrospectively reviewed. The log rank method was used for univariate analysis and Cox proportional hazards regression was used for multivariate analysis. The patients were stratified as follows: Stage III, 92 (67.2{\%}), Stage IV, 45 (32.8{\%}); Grade 1, 15 (10.9{\%}), Grade 2, 47 (34.3{\%}), Grade 3, 67 (48.9{\%}); adenocarcinoma, 93 (67.9{\%}), adenosquamous, 18 (13.1{\%}), adenoacanthoma, 2 (1.5{\%}), clear cell, 1 (0.7{\%}), papillary serous, 23 (16.8{\%}). Using univariate analysis, median survival was 1.71 years for Stage III versus 0.68 years for Stage IV. Median survival based on treatment was as follows: radiotherapy (RT) only (n = 16), 0.89 years, surgery only (n = 36), 0.75 years, preoperative RT + surgery (n = 7), 2.5 years, surgery + postoperative RT (n = 56), 2.63 years, and other treatments (hormonal only n = 12, chemotherapy only n = 1, and no treatment n = 9), 0.6 years. Patients with vaginal extension survived a median of 0.82 years, versus 2.49 years without this factor (P = 0.002). Patients with clinically apparent parametrial involvement survived a median of 0.70 years versus 2.65 years without this factor (P = 0.0003). Multivariate analysis was possible via a surgical database (n = 99). Age >60 (P = 0.01), parametrial involvement (P = 0.04), and abdominal metastases (P = 0.003) were significant prognostic indicators. Papillary or clear cell histology, advanced grade, and mode of treatment were not significant. Patients with abdominal metastases or parametrial extension of tumor have a significant decrease in mean survival.",
author = "Kian Behbakht and Yordan, {Edgardo L.} and Caroline Casey and {De Geest}, Koenraad and Massad, {L. Stewart} and Kirschner, {Caroline V.} and Wilbanks, {George D.}",
year = "1994",
month = "12",
doi = "10.1006/gyno.1994.1307",
language = "English (US)",
volume = "55",
pages = "363--367",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Prognostic Indicators of Survival in Advanced Endometrial Cancer

AU - Behbakht, Kian

AU - Yordan, Edgardo L.

AU - Casey, Caroline

AU - De Geest, Koenraad

AU - Massad, L. Stewart

AU - Kirschner, Caroline V.

AU - Wilbanks, George D.

PY - 1994/12

Y1 - 1994/12

N2 - Advanced endometrial cancer represents 14% of all stages but 54% of all deaths attributed to endometrial cancer. From 1973 to 1990, the charts of 137 patients with endometrial cancer (Stage III and IV) treated by the section of Gynecologic Oncology at Rush Medical College were retrospectively reviewed. The log rank method was used for univariate analysis and Cox proportional hazards regression was used for multivariate analysis. The patients were stratified as follows: Stage III, 92 (67.2%), Stage IV, 45 (32.8%); Grade 1, 15 (10.9%), Grade 2, 47 (34.3%), Grade 3, 67 (48.9%); adenocarcinoma, 93 (67.9%), adenosquamous, 18 (13.1%), adenoacanthoma, 2 (1.5%), clear cell, 1 (0.7%), papillary serous, 23 (16.8%). Using univariate analysis, median survival was 1.71 years for Stage III versus 0.68 years for Stage IV. Median survival based on treatment was as follows: radiotherapy (RT) only (n = 16), 0.89 years, surgery only (n = 36), 0.75 years, preoperative RT + surgery (n = 7), 2.5 years, surgery + postoperative RT (n = 56), 2.63 years, and other treatments (hormonal only n = 12, chemotherapy only n = 1, and no treatment n = 9), 0.6 years. Patients with vaginal extension survived a median of 0.82 years, versus 2.49 years without this factor (P = 0.002). Patients with clinically apparent parametrial involvement survived a median of 0.70 years versus 2.65 years without this factor (P = 0.0003). Multivariate analysis was possible via a surgical database (n = 99). Age >60 (P = 0.01), parametrial involvement (P = 0.04), and abdominal metastases (P = 0.003) were significant prognostic indicators. Papillary or clear cell histology, advanced grade, and mode of treatment were not significant. Patients with abdominal metastases or parametrial extension of tumor have a significant decrease in mean survival.

AB - Advanced endometrial cancer represents 14% of all stages but 54% of all deaths attributed to endometrial cancer. From 1973 to 1990, the charts of 137 patients with endometrial cancer (Stage III and IV) treated by the section of Gynecologic Oncology at Rush Medical College were retrospectively reviewed. The log rank method was used for univariate analysis and Cox proportional hazards regression was used for multivariate analysis. The patients were stratified as follows: Stage III, 92 (67.2%), Stage IV, 45 (32.8%); Grade 1, 15 (10.9%), Grade 2, 47 (34.3%), Grade 3, 67 (48.9%); adenocarcinoma, 93 (67.9%), adenosquamous, 18 (13.1%), adenoacanthoma, 2 (1.5%), clear cell, 1 (0.7%), papillary serous, 23 (16.8%). Using univariate analysis, median survival was 1.71 years for Stage III versus 0.68 years for Stage IV. Median survival based on treatment was as follows: radiotherapy (RT) only (n = 16), 0.89 years, surgery only (n = 36), 0.75 years, preoperative RT + surgery (n = 7), 2.5 years, surgery + postoperative RT (n = 56), 2.63 years, and other treatments (hormonal only n = 12, chemotherapy only n = 1, and no treatment n = 9), 0.6 years. Patients with vaginal extension survived a median of 0.82 years, versus 2.49 years without this factor (P = 0.002). Patients with clinically apparent parametrial involvement survived a median of 0.70 years versus 2.65 years without this factor (P = 0.0003). Multivariate analysis was possible via a surgical database (n = 99). Age >60 (P = 0.01), parametrial involvement (P = 0.04), and abdominal metastases (P = 0.003) were significant prognostic indicators. Papillary or clear cell histology, advanced grade, and mode of treatment were not significant. Patients with abdominal metastases or parametrial extension of tumor have a significant decrease in mean survival.

UR - http://www.scopus.com/inward/record.url?scp=0028657626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028657626&partnerID=8YFLogxK

U2 - 10.1006/gyno.1994.1307

DO - 10.1006/gyno.1994.1307

M3 - Article

VL - 55

SP - 363

EP - 367

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -